武汉艾必赛生物有限公司推荐Research Grade Retatrutide ,精品抗体

链接：https://www.abinscience.cn/product/71/27542.html

名称：Research Grade Retatrutide

货号：SW328046

种属反应性：Human

应用：ELISA, Functional assay, Research in vivo

同种型：Biosynthetic peptide.

种属：Human

克隆类型：Monoclonal

靶标：GLP-1 receptor, Glucagon-like peptide 1 receptor, GLP1R, GLP-1-R, GLP-1R, Gastric inhibitory polypeptide receptor, GIPR, GIP-R, Glucose-dependent insulinotropic polypeptide receptor, GCGR, Glucagon receptor, GL-R

内毒素水平：Please contact with the lab for this information.

纯度：>95% as determined by HPLC.

纯化方式：Purified by HPLC.

Accession号：P43220 & P48546 & P47871

状态：Liquid

产品使用信息：应用方法ELISA ；稀释比例1:2000-1:20000

用途范围：仅用于科研

储存：Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

产品介绍：Research Grade Retatrutide (LY3437943)｜SW328046 是艾必赛生物（abinScience）推出的研究级三重代谢受体激动剂对照试剂，属药物对照品类，可特异性激活人源GIPR、GLP-1R、GCGR三个靶点，适用于ELISA（标准品/包被原）、功能性实验（受体活性验证、细胞药效初筛）、科研体内（代谢疾病模型药效/药代研究）场景。该产品为生物合成多肽，经HPLC纯化，纯度>95%（HPLC），以液体形式保存于0.01M PBS（pH 7.4）中；短期2-8°C使用，长期建议-20°C至-80°C保存12个月，避免反复冻融。（RUO，仅限科研/非临床用途）

Retatrutide是礼来（Eli Lilly）在研的长效三靶激素受体激动剂（研发代号LY3437943），为修饰多肽类药物，可同时激活葡萄糖依赖性促胰岛素多肽（GIP）、胰高血糖素样肽-1（GLP-1）、胰高血糖素三条通路，协同调控血糖、抑制摄食、促进脂肪分解，临床开发方向覆盖肥胖、2型糖尿病、非酒精性脂肪性肝炎（NASH）等代谢性疾病，目前披露的II/III期数据表现优于已上市的GLP-1单靶、GLP-1/GIP双靶同类药物。其作用的三个受体均为代谢领域核心热门靶点，该研究级Retatrutide可作为药物研发过程中的阳性对照、质控参照、PK/PD标准品，也适用于靶点机制研究、竞品筛选等科研场景。

产品购买联系方式：027-87433958/17302791434

邮箱：info@abinscience.com

参考文献：

Retatrutide-A Game Changer in Obesity Pharmacotherapy. PMID: 40563436

Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. PMID: 37366315

The power of three: Retatrutide's role in modern obesity and diabetes therapy. PMID: 39515565

Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. PMID: 41090431

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. PMID: 37385280

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. PMID: 38858523

Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. PMID: 39318607

Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. PMID: 40291085

Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. PMID: 40609566

Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials. PMID: 40728138

Retatrutide. PMID: 39429457

Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. PMID: 42250575

A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. PMID: 38367045

Retatrutide showing promise in obesity (and type 2 diabetes). PMID: 37947489

Efficacy of Tirzepatide, Retatrutide, and Semaglutide for Weight Loss in Obese Individuals Without Diabetes. PMID: 40583149

Retatrutide in type 2 diabetes mellitus and obesity: an overview. PMID: 41785010

Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply. PMID: 37888927

Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA. PMID: 40685589

Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. PMID: 38843460

详情请咨询 abinScience 亚洲区官方子公司 —— 武汉艾必赛生物技术有限公司
官方网址：【中文】https://www.abinscience.cn

【英文】https://www.abinscience.com

武汉艾必赛生物技术有限公司成立于 2023 年，是 abinScience 在亚洲地区设立的官方全资子公司，全面负责 abinScience 品牌在亚太市场的科研试剂推广、销售及技术支持工作。
依托严格的产品研发体系和国际化的质量管理标准，武汉艾必赛与 AtaGenix、ProteoGenix 等知名品牌保持长期战略合作，现已构建起涵盖抗体、重组蛋白、工具酶、试剂盒、实验耗材在内的多品类供应体系，面向区域内科研机构、高校实验室与生物医药企业，提供稳定、高效、可信赖的产品与服务。
核心业务覆盖：
? 抗体产品（单抗、多抗、重组抗体等）
? 蛋白与多肽试剂（标签蛋白、功能蛋白等）
? 分子与细胞实验相关耗材
? 定制化研发服务（蛋白表达、抗体定制、亲和力成熟等）
? 科研供应链整合与项目配套支持
武汉艾必赛始终秉持“Empowering Bioscience Discovery”的理念，为亚太地区的生命科学研究持续注入高质量动能。